Positive results for liquid botulinum toxin
Global pharmaceutical company Galderma’s liquid formulation of botulinum toxin type A has achieved positive results for the treatment of glabellar lines in a phase 2 clinical trial.
Global pharmaceutical company Galderma’s liquid formulation of botulinum toxin type A has achieved positive results for the treatment of glabellar lines in a phase 2 clinical trial.
Medical aesthetic company Novus medical has launched a new device designed to treat snoring, called the Somnilase.
US hair loss technology provider Kerastem has confirmed that patients who underwent the Phase 2 clinical trial in early-stage hair loss achieved an increase in mean terminal hair count in men with early hair loss when compared to the control group. Based on these results, Kerastem plans to begin a Phase 3 clinical trial later this year.
Global pharmaceutical company Allergan has launched Juvéderm VOLUX, a hyaluronic acid injectable gel that uses the existing VYCROSS patented technology.
London-based clinic MyBreast Cosmetic Surgery has been chosen as the only UK clinic to participate in an international clinical trial to determine the safety and effectiveness of a number of breast implants including the SmoothSilk, Round and Ergonomix from Motiva Implants.